| Immune-phenotyping of peripheral blood mononuclear cells from patients with early triple-negative breast cancer: Identification of a systemic immunosuppressive CD3+ CD4+ CD39+ … BL Rapoport, N Chicken, P Meyer, R Anderson, L Heyman, T Smit, ... Journal of Clinical Oncology 42 (16_suppl), 3040-3040, 2024 | | 2024 |
| Relationships of emerging biomarkers of cancer cachexia with quality of life, appetite, and cachexia M Lipshitz, J Visser, R Anderson, DG Nel, T Smit, HC Steel, BL Rapoport Supportive Care in Cancer 32 (6), 349, 2024 | 1 | 2024 |
| Strategies to optimize the promise of checkpoint-targeted anti-cancer therapy BL Rapoport, R Anderson Immunotherapy, 1-4, 2024 | | 2024 |
| Transforming growth factor-β1 and soluble co-inhibitory immune checkpoints as putative drivers of immune suppression in patients with basal cell carcinoma MCM Kgokolo, NZ Malinga, HC Steel, PWA Meyer, T Smit, R Anderson, ... Translational Oncology 42, 101867, 2024 | 1 | 2024 |
| Patient-reported symptom monitoring: using (big) data to improve supportive care at the macro-, meso-, and micro-levels Y Wang, MJ Allsop, JB Epstein, D Howell, BL Rapoport, P Schofield, ... Supportive Care in Cancer 32 (3), 182, 2024 | | 2024 |
| Image‐based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno‐oncology Biomarker Working Group on Breast Cancer CA Jahangir, DB Page, G Broeckx, CA Gonzalez, C Burke, C Murphy, ... The Journal of pathology 262 (3), 271-288, 2024 | 1 | 2024 |
| Filgrastim biosimilar (EP2006): a review of 15 years’ post-approval evidence P Gascón, N Harbeck, BL Rapoport, R Anderson, I Brueckmann, S Howe, ... Critical Reviews in Oncology/Hematology, 104306, 2024 | | 2024 |
| 2023 MASCC and ESMO guideline update for the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting J Herrstedt, R Clark-Snow, CH Ruhlmann, A Molassiotis, I Olver, ... ESMO open 9 (2), 102195, 2024 | 16 | 2024 |
| Standardised flow cytometric protocol for the detection of immune cells subsets in breast cancer patients. N Chicken, P Meyer, R Anderson, B Rapoport, C Worsley | | 2024 |
| Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents—updated MASCC/ESMO consensus recommendation K Jordan, A Chan, RJ Gralla, F Jahn, B Rapoport, CH Ruhlmann, ... Supportive Care in Cancer 32 (1), 53, 2024 | 6 | 2024 |
| 2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and … BL Rapoport, J Herrstedt, RC Snow, V Radhakrishnan, M Saito, ... Supportive Care in Cancer 32 (1), 36, 2024 | 5 | 2024 |
| Emerging markers of cancer cachexia and their relationship to sarcopenia M Lipshitz, J Visser, R Anderson, DG Nel, T Smit, HC Steel, B Rapoport Journal of Cancer Research and Clinical Oncology 149 (19), 17511-17527, 2023 | 5 | 2023 |
| 1150P Transforming growth factor-beta-1 and soluble co-inhibitory immune checkpoints as putative drivers of immune suppression in advanced basal cell carcinoma BL Rapoport, R Anderson, S Siwele, H Steel, L Kwofie, M Kgokolo, T Smit, ... Annals of Oncology 34, S688, 2023 | | 2023 |
| 261P Dysregulation of immune checkpoint proteins in newly-diagnosed early breast cancer patients undergoing neoadjuvant chemotherapy: A comparison between TNBC and non-TNBC … BL Rapoport, H Steel, CA Benn, S Nayler, T Smit, L Heyman, L Kwofie, ... Annals of Oncology 34, S287, 2023 | | 2023 |
| 490P Metastatic breast cancer is associated with increased levels of soluble forms of TIM-3 and LAG-3 and decreased levels of soluble forms of GITR, GITR-L, CD27, CD28, CD40 … T Smit, BL Rapoport, H Steel, L Heyman, CA Benn, R Anderson Annals of Oncology 34, S387, 2023 | | 2023 |
| Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno‐Oncology Biomarker Working Group on Breast … DB Page, G Broeckx, CA Jahangir, S Verbandt, RR Gupta, J Thagaard, ... The Journal of pathology 260 (5), 514-532, 2023 | 12 | 2023 |
| Pitfalls in machine learning‐based assessment of tumor‐infiltrating lymphocytes in breast cancer: A report of the International Immuno‐Oncology Biomarker Working Group on … J Thagaard, G Broeckx, DB Page, CA Jahangir, S Verbandt, Z Kos, ... The Journal of pathology 260 (5), 498-513, 2023 | 17 | 2023 |
| Pro-tumorigenic and thrombotic activities of platelets in Lung Cancer R Anderson, BL Rapoport, HC Steel, AJ Theron International Journal of Molecular Sciences 24 (15), 11927, 2023 | 4 | 2023 |
| Transforming growth factor-b1 and soluble co-inhibitory immune checkpoints as putative drivers of immune suppression in advanced basal cell carcinoma. BL Rapoport, R Anderson, N Malinga, HC Steel, P Meyer, T Smit, ... Journal of Clinical Oncology 41 (16_suppl), 9567-9567, 2023 | | 2023 |
| Dysregulation of immune checkpoint proteins in patients with newly diagnosed early breast cancer undergoing neoadjuvant chemotherapy: A comparison between patients with triple … T Smit, BL Rapoport, HC Steel, C Benn, S Nayler, L Heyman, AJ Theron, ... Journal of Clinical Oncology 41 (16_suppl), e14546-e14546, 2023 | | 2023 |
